Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014', provides an overview of the Female Hypoactive Sexual Desire Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Female Hypoactive Sexual Desire Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Overview 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Comparative Analysis 8
Female Hypoactive Sexual Desire Disorder - Therapeutics under Development by Companies 9
Female Hypoactive Sexual Desire Disorder - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Female Hypoactive Sexual Desire Disorder - Products under Development by Companies 13
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development 14
Apricus Biosciences, Inc. 14
Palatin Technologies, Inc. 15
ANI Pharmaceuticals, Inc. 16
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
flibanserin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
testosterone - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
alprostadil - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
bremelanotide - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(sildenafil + testosterone) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(bupropion hydrochloride + trazodone hydrochloride) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(buspirone hydrochloride + testosterone) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Female Hypoactive Sexual Desire Disorder - Recent Pipeline Updates 39
Female Hypoactive Sexual Desire Disorder - Dormant Projects 48
Female Hypoactive Sexual Desire Disorder - Product Development Milestones 49
Featured News & Press Releases 49
Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD 49
Sep 04, 2012: BioSante Pharma Announces Positive LibiGel Phase III Safety Data Review And Decision To Conclude Safety Study 50
Feb 20, 2012: S1 Pharma Submits IND Application For SIP-104 For Treatment Of Hypoactive Sexual Desire Disorder 51
Jan 31, 2012: BioSante Pharmaceuticals Provides Update On Clinical Development Of LibiGel 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2014 7
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences, Inc., H2 2014 14
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies, Inc., H2 2014 15
Female Hypoactive Sexual Desire Disorder - Pipeline by ANI Pharmaceuticals, Inc., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Assessment by Combination Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Female Hypoactive Sexual Desire Disorder Therapeutics - Recent Pipeline Updates, H2 2014 39
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H2 2014 48